{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T02:09:09Z","timestamp":1775441349902,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis is a leading infectious cause of death globally and the main cause among those with HIV. TB preventive treatment (TPT) is key for preventing TB in people with HIV (PWH). Healthcare workers often worry about adverse effects of TPT regimens, including breakthrough TB\u2013active TB during treatment. The burden of breakthrough TB remains largely unknown. This study aimed to determine the incidence and factors associated with breakthrough TB in PWH receiving HIV care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed the nationwide electronic patient management system (EPMS) for HIV care and TB registers in Namibia, following PWH registered for HIV care to determine TB incidence before, during and after TPT and applying logistic regression to determine factors associated with breakthrough TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 334,606 PWH reviewed, 46,199 developed TB before, during, or after receiving TPT while being followed up for HIV care. PWH were followed for 114,667 patient\u2010years (PYs) while receiving TPT, with breakthrough TB incidence of 1.40 per 100 PYs (95% CI: 1.33\u20131.47). The 1790 true breakthrough cases had a median age of 37 (IQR 30\u201345). Median time to breakthrough TB was 2.5\u2009months. Only 43 (2.4%) cases were drug\u2010resistant TB. In a logistic regression model comparing breakthrough versus non\u2010breakthrough TB cases, receiving ART increased breakthrough TB risk (aOR\u2009=\u20092.88; 95% CI: 1.07\u20137.78). The 3\u2009month isoniazid\u2010rifapentine TPT regimen showed lower risk (aOR\u2009=\u20090.46; 95% CI: 0.36\u20130.63) than the 6\u2009month isoniazid regimen, while 9H increased risk (aOR\u2009=\u20091.44; 95% CI: 1.18\u20132.52) but incidence rates were comparable between the regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The incidence of breakthrough TB was low at 1.4 per 100 PYs of TPT provision but indicating a need for improved screening of PWH before TPT. The incidence rate of TB among PWH during and after the shorter TPT regimen (3HP) is comparable to that of the 6H and 9H regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tmi.70107","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:39:12Z","timestamp":1771508352000},"page":"560-566","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breakthrough Tuberculosis in a Large Cohort of People Living With\n                    <scp>HIV<\/scp>\n                    on Preventive Treatment"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1764-3574","authenticated-orcid":false,"given":"N.","family":"Ruswa","sequence":"first","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Veterinary Medicine University of Namibia  Windhoek Namibia"},{"name":"National TB and Leprosy Programme, Directorate of Special Programmes Ministry of Health and Social Services  Windhoek Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"G\u00fcnther","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Veterinary Medicine University of Namibia  Windhoek Namibia"},{"name":"Department of Pulmonology, Allergology and Clinical Immunology, Inselspital, Bern University Hospital University of Bern  Bern Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Claassens","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Health Sciences and Veterinary Medicine University of Namibia  Windhoek Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.54394\/CJQU6666","volume-title":"Global Tuberculosis Report 2024","author":"World Health Organization","year":"2024"},{"key":"e_1_2_10_3_1","unstructured":"ICAP MoHSS CDC \u201cNamibia Population\u2010Based HIV Impact Assessment (Preliminary Report) \u201d 2018."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwz172"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15841"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001270"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211688"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018327"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005260"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1205.050681"},{"key":"e_1_2_10_11_1","unstructured":"NTLP \u201cNational Guidelines for the Management of TB \u201d 2006 p 1\u201325."},{"key":"e_1_2_10_12_1","unstructured":"Ministry of Health and Social Services \u201cNational Guidelines for the Management of Tuberculosis \u201d 2012."},{"key":"e_1_2_10_13_1","first-page":"1","volume-title":"National Guidelines for the Management of Tuberculosis","author":"Ministry of Health and Social Services","year":"2019"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000171.pub3"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30299-X"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214289"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60204-3"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00499-5"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-7577"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2016.03.002"},{"key":"e_1_2_10_21_1","unstructured":"Ministry of Health and Social Services \u201cNational Guidelines for Antiretroviral Therapy \u201d Windhoek 2016."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2019.1704540"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.5588\/pha.22.0016"},{"key":"e_1_2_10_24_1","volume-title":"Guidelines Guideline on When to Start Antiretroviral Therapy and on Pre\u2010Exposure Prophylaxis for HIV","author":"World Health Organization","year":"2015"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000535"},{"issue":"2","key":"e_1_2_10_26_1","first-page":"75","article-title":"Isoniazid Prophylactic Therapy for Tuberculosis in HIV\u2010Seropositive Patients\u2014A Least\u2010Cost Analysis","volume":"85","author":"Masobe P.","year":"1995","journal-title":"South African Medical Journal"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0962-8479(92)90033-G"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0589-3"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.70107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tmi.70107","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.70107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T01:05:03Z","timestamp":1775437503000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.70107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/tmi.70107"],"URL":"https:\/\/doi.org\/10.1111\/tmi.70107","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"2025-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}